Neurogene Inc.
NGNE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404644
No open-market purchases or sales by Neurogene Inc. insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $544.4M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Neurogene Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 36 | 31 | −5 |
| SharesConverted for a 1-for-5 split | 3.46M | 3.65M | +192.5K (+5.6%) |
| Value | $14.3M | $14.4M | +$72.2K (+0.5%) |
New holders (5)
Institutions that held Neurogene Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 310,000 | $1.22M | 0.00% |
| Nantahala Capital Management, LLC | 299,999 | $1.18M | 0.15% |
| CVI Holdings, LLC | 24,916 | $98.4K | 0.20% |
| Susquehanna International Group, LLP | 13,154 | $52.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 823 | $3.25K | 0.00% |
Sold out (10)
Institutions that held Neurogene Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Lynx1 Capital Management LP | 3,094,554 | $2.57M |
| Western Standard LLC | 860,882 | $714.5K |
| Privium Fund Management (UK) Ltd | 117,200 | $94.9K |
| Alta Fundamental Advisers LLC | 89,702 | $74.5K |
| HighTower Advisors, LLC | 48,409 | $40.0K |
| Simon Quick Advisors, LLC | 23,428 | $19.4K |
| Bank of New York Mellon Corp | 14,372 | $11.9K |
| Federated Hermes, Inc. | 1,555 | $1.29K |
| Barclays PLC | 163 | $135 |
| Royal Bank of Canada | 592 | $0 |